Biopharmaceutical Innovation and Regulatory Harmonisation in Emerging Economies: A Comprehensive Analysis of Brazil, China, India, and South Africa

Abstract

Introduction: Emerging economies are changing the playing?field of global biopharmaceutical innovation and international review mechanisms should be adjusted accordingly. However, heterogenous regulatory frameworks and innovation potential prevent sustainable global market?access with truly affordable health care. Analyses of biopharmaceutical innovation trajectories, regulatory environments and policy ecosystems in these four market-pairs can inform opportunities for improved?collaboration and patient access. Methods: We performed an in-depth analysis of the innovation pipelines and biopharmaceutical industries in Brazil, China, India,?and South Africa. Information was retrieved from?regulatory databases, company reports, clinical trial registries and peer-reviewed sources (2018-2024). We examined 376 drug candidates from 66 companies, analysing their innovation attributes, regulatory approval methods, and policy environments. Other information about trends in clinical trials, timelines?for regulatory approval and recent policy developments were abstracted in a systematic manner. Results and Discussion: Analysis showed 376 biopharmaceutical candidates in?development, about 60% of which were new chemical or molecular entities. China still had the highest?number of New Molecular Entity (NME) at 46 in 2024 and India's biopharmaceutical sector accounted for 49% of the country's total biopharmaceutical output. Regulatory timelines varied significantly—from 21 days under China’s pilot programme, to 10–14 months in Brazil, and up to approximately four years historically in South Africa. The gap in clinical research activity between BRICS and G7 countries decreased by 68.6% between 2018 and 2022. Challenges included limited resources, regulatory complexity, and low levels of harmonisation, while progress was driven by government support, attention to local health needs, and international collaboration. Conclusion: There is great potential in biopharmaceutical innovation in BRICS, but there is a requirement?for regulatory harmonisation to obtain global impact. Policy recommendations include risk-based assessments,?installation of reliance mechanisms, public-private partnerships and establishment of regional harmonisation platforms. These measures could accelerate the arrival of new treatments while maintaining safety standards and supporting the growth of a viable business environment